Engaged in biopharmaceutical development, this company focuses on creating innovative therapies, including diagnostic tools and treatments for cancers, leveraging its proprietary Affimer technology.
2006
United Kingdom
51 - 200 employees
Biotechnology
$25M - 100M in revenue
Not profitable
CO2e per visit (g)
Industry benchmark